CDXS News & Events

The company said, "We expect our existing cash, cash equivalents and short-term investments will be sufficient to fund our planned operations through the end of 2027."

Reports Q4 revenue $38.92M, consensus $35.83M. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis Manufacturing Platform to customers in the RNAi industry. We've secured multiple contracts with leading pharma, high growth biotech, and top tier CDMOs, underscoring the commercial potential of our platform," said Alison Moore, president and CEO at Codexis. "We achieved many technological advancements this year, including producing a 10 g siRNA batch utilizing our fully enzymatic synthesis process, as well as a 3 kg siRNA batch from one of our customers utilizing our ligase product. As we look to the year ahead, we are focused on demonstrating the value of our technology to our customers through expanded partnerships, and continuing our history of innovation in oligonucleotide manufacturing."

Codexis announced it has entered into an agreement with "an innovator pharmaceutical company" to manufacture 50 grams of small interfering RNA using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication. Under the terms of the agreement, Codexis will produce siRNA material to support its partner's preclinical program. "We are excited about this relationship as it represents an important entry point into what could become a high-volume opportunity," said Alison Moore, President and Chief Executive Officer of Codexis. "Engagements like this illustrate our path to growth as we continue to expand partnerships and position the platform for potential commercial-scale applications."